Brand Intelligence Graph
Company Overview
About Infant Bacterial Therapeutics
Infant Bacterial Therapeutics (IBT) is a Swedish biopharma company developing Lactobacillus reuteri DSM17938 — a probiotic bacterial strain — as a regulated drug (live biotherapeutic product) to prevent necrotizing enterocolitis (NEC) in premature infants. NEC is a devastating gastrointestinal emergency affecting 1–7% of premature newborns, with 30% mortality and severe long-term outcomes in survivors. No approved preventive treatments exist, despite decades of evidence suggesting certain probiotic strains reduce NEC incidence.
Business Model & Competitive Advantage
IBT's approach treats a well-characterized probiotic strain as a pharmaceutical product with rigorous GMP manufacturing, safety testing, and clinical development — a regulatory path enabled by the FDA and EMA's live biotherapeutic framework. The company's Phase 3 PROPREMS-3 trial across 40+ neonatal intensive care units is among the largest neonatal probiotic trials ever conducted, with results expected in 2026.
Competitive Landscape 2025–2026
Founded in 2014 and listed on Nasdaq First North in Stockholm, IBT has partnerships with major neonatal nutrition companies and has raised significant funding to complete the pivotal trial. Regulatory approval would create the first FDA/EMA-approved preventive therapy for NEC, addressing a critical unmet need in neonatal intensive care.
Key Differentiators
Emerging Innovator
Infant Bacterial Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Infant Bacterial Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Infant Bacterial Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Infant Bacterial Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Infant Bacterial Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →